Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06475547

Inflammation and Postoperative Atrial Fibrillation in Cardiac Surgery

Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery, marked by an irregular and rapid heart rate, and associated with increased morbidity, longer hospital stays, and higher costs. Its complex pathophysiology involves atrial remodeling, inflammation, and autonomic dysregulation. Surgical trauma and cardiopulmonary bypass trigger an inflammatory response, releasing cytokines. Epicardial fat around the heart secretes pro-inflammatory cytokines, and its increased thickness is linked to higher inflammation and atrial fibrillation. This study uses RNA sequencing (RNA-seq) to profile gene expression in epicardial fat, identifying key genes involved in inflammation and metabolism. By comparing patients with and without POAF, RNA-seq reveals differentially expressed genes associated with postoperative atrial fibrillation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Odense University Hospital, Cardiac Surgery Department

Odense, 5000, Denmark

Location status: Recruiting

Location contact

Lytfi Krasniqi, MD

CONTACT

[email protected]

004524638899

About this study

Postoperative Atrial Fibrillation (POAF) after Cardiac Surgery Postoperative atrial fibrillation is a common complication following cardiac surgery, characterized by irregular and often rapid heart rate. It is associated with increased morbidity, prolonged hospital stays, and higher healthcare costs. The pathophysiology of POAF is complex and multifactorial, involving atrial structural and electrical remodeling, inflammation, and autonomic dysregulation.

Inflammation and Epicardial Fat Inflammation plays a significant role in the development of POAF. Surgical trauma and cardiopulmonary bypass trigger a systemic inflammatory response, releasing cytokines and other inflammatory mediators. Epicardial fat, the visceral fat depot around the heart, is an active endocrine organ secreting pro-inflammatory cytokines and adipokines. Increased epicardial fat thickness is associated with higher levels of inflammation and has been implicated in the pathogenesis of atrial fibrillation.

RNA isolation and sequencing RNA sequencing (RNA-seq) can be used to investigate gene expression in epicardial fat in several impactful ways. RNA-seq can profile gene expression to identify active genes in epicardial fat and their expression levels, revealing key genes involved in inflammation and metabolism. By comparing gene expression between groups, such as patients with and without POAF, RNA-seq can identify differentially expressed genes associated with atrial fibrillation.

RNA-seq analyses The RNA sequencing data files were aligned to the hg38 reference genome using the Spliced Transcripts Alignment to a Reference (STAR) aligner and read counts in genes were quantified. The resulting data matrix with unnormalized counts was loaded into RStudio together with patient metadata information (e.g., age, gender, BMI, smoking). Differential expression analyses were conducted with DESeq2 using adjustment for different variables, including type of tissue, age of patients, gender, and BMI.

Hypothesis The hypothesis that POAF may be influenced by pre-existing inflammation in epicardial fat, in addition to the inflammation caused by surgical trauma.

Objective:

To compare inflammatory gene expression in epicardial fat between patients who develop POAF and those who do not after elective cardiac surgery.

Study Design:

A prospective cohort study including patients undergoing first-time elective cardiac surgery.

Participants:

Inclusion criteria

Patients undergoing first-time elective cardiac surgery. Exclusion criteria: Patients with previous cardiac surgeries or emergency surgeries.

Groups:

POAF Group: Patients who develop POAF. Non-POAF Group: Patients who do not develop POAF.

Sample Collection:

Epicardial fat samples will be collected during the time of surgery.

RNA Isolation and Sequencing:

Homogenize adipose tissue in TRIzol using ceramic beads (Fastprep 24, MPBio). Purify RNA using EconoSpin columns (Epoch). Prepare RNA libraries with NEBNext Ultra II RNA Library Prep Kit for Illumina. Perform paired-end sequencing on the NovaSeq 6000 platform (Illumina).

Data Analysis:

Align RNA-seq data to the hg38 genome using STAR aligner. Quantify gene counts and perform differential expression analysis using DESeq2. Adjust for variables such as tissue type, age, gender, and BMI.

Outcome Measures:

Compare inflammatory gene expression profiles between POAF and Non-POAF groups at the time of surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18
  • Informed consent

Exclusion criteria

  • Incompetent individuals
  • General poor health condition at the time of inclusion
  • Reoperation

Treatment and study plan

descriptive

Other

This study is observational and does not involve any clinical intervention. The primary procedure involves the collection of epicardial fat tissue samples. The collected samples are then processed and analyzed to compare inflammatory gene expression between the two groups. The analysis includes RNA sequencing to identify differentially expressed genes associated with atrial fibrillation and inflammation.

Primary outcomes

  1. Differential expression of genes

    Time frame: The sample is taken at the time of surgery.

    The primary endpoint of this study is to identify differentially expressed (DE) genes using RNA sequencing (RNA-seq) data. Post-sequencing, we will utilize the default settings and statistical methods provided by DESeq2 to determining statistically significant differences in gene expression between the experimental conditions.

    The gene signal is measured in normalized counts per kilobase or in Fragments Per Kilobase of transcript per Million mapped reads.

Study contacts

Contact information is provided by the study sponsor or research team.

Lytfi Krasniqi, MD

CONTACT

[email protected]

65412404

Sponsors and collaborators

Lead sponsor

Odense University Hospital

Other

Registry information

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Jun 26, 2024
Registry last updated
Aug 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.